Crohn’s disease: Ustekinumab safe and effective in a real-world setting

Key clinical point: Ustekinumab was effective and relatively safe in a real-world cohort of patients with Crohn’s disease (CD).

Major finding: After 104 weeks of ustekinumab treatment, 34.0% of patients were in corticosteroid-free clinical remission (Cf-CR). Among patients who were in Cf-CR at week 24, 48.1% remained at Cf-CR at week 104. Lack of response (61.7%) and loss of response (18.3%) were the main reasons for treatment discontinuation. No new safety signals were identified.

Study details: Findings are from a cohort study of 252 patients with CD who initiated ustekinumab and completed at least 2 years of follow-up.

,

Disclosures: No information on funding was available. The authors declared serving as a speaker, consultant, principal investigator, advisory board member for and/or receiving sponsorship, grants/honoraria, advisory, and/or speaker fees from multiple sources.

Source: Straatmijer T et al. J Crohns Colitis. 2021 Apr 28. doi: 10.1093/ecco-jcc/jjab081.